SABCS 2024 Insights: Impact of Oncotype DX Risk Stratification on Chemotherapy Use and Survival Outcomes in HR Node- eBC

Economic Impact of Oncotype DX on Breast Cancer Management | OncLive

Conheça o Oncotype DX®

Dr. Tripathy on the Oncotype DX Assay Recurrence Score | OncLive

Dr. Febbo Explains the Oncotype DX Genomic Prostate Score | OncLive

The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows

Oncotype DX Used for Patients With Breast Cancer to Guide Therapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows | Facebook

Test Oncotype DX Breast Recurrence Score®: test genomowy dla kobiet z rakiem piersi